InDex Pharmaceuticals Holding AB (publ), a Sweden-based pharmaceutical development company, announced on Wednesday that it has entered into a license agreement with Viatris Pharmaceutical Japan Inc., to register and commercialise cobitolimod in Japan, intended for the treatment of ulcerative colitis.
Cobitolimod, a TLR9 agonist, is being assessed in the global phase III program CONCLUDE, as a novel treatment for moderate to severe ulcerative colitis.
Under the terms of the agreement, Viatris Japan will pay InDex an upfront fee of USD10m for the exclusive rights to commercialise cobitolimod in Japan. In addition, InDex is eligible to receive development and sales milestone payments of up to USD40m. Viatris Japan will also pay up to double-digit percentage royalties based on its net sales for the product in Japan.
InDex will continue to fund all development which incorporates the completion of the global phase III-program CONCLUDE, including a cohort of Japanese patients in Induction Study 2 and a PK study in Japanese patients prior to filing. Viatris Japan will fund all regulatory and commercialization expenses, as well as any additional Japanese-specific studies required in Japan.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic